Orphazyme A/S (ORPH) Stock Price, News & Analysis

Company Overview

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.57 to $2.21
• 52-Week Range: N/A
• Volume: 941,400 shs
• Average Volume: 1.37 million shs
• Market Capitalization: $30.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ORPH Stock Analysis - Frequently Asked Questions

When did Orphazyme A/S IPO?

Orphazyme A/S (ORPH) raised $100 million in an initial public offering on Tuesday, September 29th 2020. The company issued 7,600,000 shares at $13.13 per share. BofA Securities, Cowen and Guggenheim Securities served as the underwriters for the IPO and Danske Markets was co-manager.

What other stocks do shareholders of Orphazyme A/S own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Orphazyme A/S investors own include AMC Entertainment (AMC), Digital World Acquisition (DWAC), NIO (NIO), Biora Therapeutics (BIOR), SNDL (SNDL), Tesla (TSLA) and Brigham Minerals (MNRL).

Company Calendar

• Today: 8/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ORPH
• CIK: 1764791
• Web: www.orphazyme.com
• Phone: 45-2898-9055
• Fax: N/A
• Employees: 141
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.14
• Current Ratio: 1.80
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.74 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 35,312,000
• Free Float: N/A
• Market Cap: $30.72 million
• Optionable: Not Optionable
• Beta: 1.68